Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Zoetis, Inc. reported second-quarter 2026 results reflecting a difficult operating environment, particularly in U.S. Companion Animal.</li><li>Global revenue was $2.5 billion, flat on a reported basis and down 1% organically.</li><li>Adjusted net income declined 2% organically, with international revenue rising 6% and U.S. revenue falling 7%.</li></ul>

Zoetis, Inc. reported second-quarter 2026 results reflecting a difficult operating environment, particularly in U.S. Companion Animal.Global revenue was $2.5 billion, flat on a reported basis and down 1% organically.Adjusted net income declined 2% organically, with international revenue rising 6% and U.S. revenue falling 7%.

Zoetis Is Not Just A Companion Animal Story — Livestock Revenue Jumps 11%!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
 <li>
Dominant Market Leader with a Wide Moat: <a href="https://smartkarma.com/entities/zoetis-inc-58b0f85f-ce54-4caf-b598-5de0e7e887d1">Zoetis </a>is the world's largest animal health company, possessing a significant market share and a wide economic moat. This is built on a foundation of a diverse and innovative product portfolio, strong brand recognition among veterinarians and pet owners, and extensive global reach.</li>
 <li>
Favorable Long-Term Industry Tailwinds: The animal health market is poised for sustained growth, driven by powerful trends such as the humanization of pets, increasing global demand for animal protein, and advancements in veterinary care. <a href="https://smartkarma.com/entities/zoetis-inc-58b0f85f-ce54-4caf-b598-5de0e7e887d1">Zoetis </a>is exceptionally well-positioned to capitalize on these long-term secular growth drivers.</li>
 <li>
Strong Financial Performance and Shareholder Returns: The company has a consistent track record of robust revenue and earnings growth, supported by high-margin products and a focus on operational efficiency. <a href="https://smartkarma.com/entities/zoetis-inc-58b0f85f-ce54-4caf-b598-5de0e7e887d1">Zoetis </a>has also demonstrated a commitment to returning capital to shareholders through consistent dividend growth.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Dominant Market Leader with a Wide Moat: Zoetis is the world's largest animal health company, possessing a significant market share and a wide economic moat. This is built on a foundation of a diverse and innovative product portfolio, strong brand recognition among veterinarians and pet owners, and extensive global reach.
  
Favorable Long-Term Industry Tailwinds: The animal health market is poised for sustained growth, driven by powerful trends such as the humanization of pets, increasing global demand for animal protein, and advancements in veterinary care. Zoetis is exceptionally well-positioned to capitalize on these long-term secular growth drivers.
  
Strong Financial Performance and Shareholder Returns: The company has a consistent track record of robust revenue and earnings growth, supported by high-margin products and a focus on operational efficiency. Zoetis has also demonstrated a commitment to returning capital to shareholders through consistent dividend growth.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

<ul>
 <li>Zoetis stands as the global leader in the animal health industry, with a diversified portfolio spanning companion animals and livestock, and a strong track record of innovation and growth.</li>
 <li>The company is navigating near-term headwinds in the U.S. companion animal market, characterized by softer demand and increased competition, which has impacted recent domestic revenue.</li>
 <li>Future growth is expected to be driven by international expansion, strategic acquisitions in high-growth areas like diagnostics (e.g., VitalRADS), and a robust R&amp;D pipeline focused on new therapies for chronic diseases.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Zoetis stands as the global leader in the animal health industry, with a diversified portfolio spanning companion animals and livestock, and a strong track record of innovation and growth.
  The company is navigating near-term headwinds in the U.S. companion animal market, characterized by softer demand and increased competition, which has impacted recent domestic revenue.
  Future growth is expected to be driven by international expansion, strategic acquisitions in high-growth areas like diagnostics (e.g., VitalRADS), and a robust R&amp;D pipeline focused on new therapies for chronic diseases.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

<ul><li>Zoetis has agreed to acquire VitalRADS, a Texas-based provider of veterinary teleradiology and imaging services, extending a commercial relationship that began in August 2025.</li><li>Under that partnership, VitalRADS supplied remote radiology interpretations through the Zoetis Virtual Laboratory, giving clinics access to specialist reviews without requiring an on-site radiologist.</li><li>The proposed transaction, expected to close in the third quarter of 2026, would add a network of board-certified veterinary specialists covering more than 25 species, alongside VitalPACS cloud-image storage, an outpatient imaging center in Cypress, Texas, and mobile ultrasound operations in Houston and Seattle.</li></ul>

Zoetis has agreed to acquire VitalRADS, a Texas-based provider of veterinary teleradiology and imaging services, extending a commercial relationship that began in August 2025.Under that partnership, VitalRADS supplied remote radiology interpretations through the Zoetis Virtual Laboratory, giving clinics access to specialist reviews without requiring an on-site radiologist.The proposed transaction, expected to close in the third quarter of 2026, would add a network of board-certified veterinary specialists covering more than 25 species, alongside VitalPACS cloud-image storage, an outpatient imaging center in Cypress, Texas, and mobile ultrasound operations in Houston and Seattle.

Zoetis Acquisition Of VitalRADS Signals A Bigger Diagnostics Push!

<ul><li>Zoetis reported first quarter 2026 financial results reflecting a complex operating environment characterized by varying performance across its key business segments and geographies.</li><li>On an organic operational basis, total company revenue was flat compared to the prior year, while adjusted net income increased by 1%.</li><li>The International segment demonstrated strong growth, with a 10% increase organically, whereas the U.S. segment faced an 8% decline.</li></ul>

Zoetis reported first quarter 2026 financial results reflecting a complex operating environment characterized by varying performance across its key business segments and geographies.On an organic operational basis, total company revenue was flat compared to the prior year, while adjusted net income increased by 1%.The International segment demonstrated strong growth, with a 10% increase organically, whereas the U.S. segment faced an 8% decline.

Zoetis’ 8% U.S. Decline: Can Livestock Growth Offset Pet-Care Pressure?

United States

Zoetis Inc discovers, develops, manufactures and commercializes animal health medicines and vaccines, with a focus on both livestock and companion animals.  The Companies products are sold in North America, Europe, Africa, Asia, Australia and Latin America.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zoetis Inc (ZTS US)

Zoetis Is Not Just A Companion Animal Story — Livestock Revenue Jumps 11%!

Zoetis, Inc. reported second-quarter 2026 results reflecting a difficult operating environment, particularly in U.S. Companion Animal. Global...

Baptista Research

Primer: Zoetis (ZTS UN) - Aug 2026

Dominant Market Leader with a Wide Moat: Zoetis is the world's largest animal health company, possessing a significant market share and a wide...

αSK Primers

Primer: Zoetis Inc (ZTS US) - Aug 2026

Zoetis stands as the global leader in the animal health industry, with a diversified portfolio spanning companion animals and livestock, and a...

αSK Primers

Zoetis Acquisition Of VitalRADS Signals A Bigger Diagnostics Push!

Zoetis has agreed to acquire VitalRADS, a Texas-based provider of veterinary teleradiology and imaging services, extending a commercial...

Baptista Research

Zoetis’ 8% U.S. Decline: Can Livestock Growth Offset Pet-Care Pressure?

Zoetis reported first quarter 2026 financial results reflecting a complex operating environment characterized by varying performance across its...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)